The flood of cheap copies of Novo Nordisk A/S’ blockbuster drug semaglutide in India is already reshaping the country’s fast-growing obesity market, cutting into Eli Lilly & Co.’s early lead and offering a first real test of how Novo may fare as its patents expire worldwide.
